stringtranslate.com

Signs and symptoms of Parkinson's disease

Parkinson's disease patient showing a typical flexed walking posture in advanced stage

Signs and symptoms of Parkinson's disease are varied. Parkinson's disease affects movement, producing motor symptoms.[1] Non-motor symptoms, which include dysautonomia, cognitive and neurobehavioral problems, and sensory and sleep difficulties, are also common.[1] When other diseases mimic Parkinson's disease, they are categorized as parkinsonism.

Motor

Four motor symptoms are considered cardinal signs in PD: slowness of movement (bradykinesia), tremor, rigidity, and postural instability.[1] Typical for PD is an initial asymmetric distribution of these symptoms, where in the course of the disease, a gradual progression to bilateral symptoms develops, although some asymmetry usually persists. Other motor symptoms include gait and posture disturbances such as decreased arm swing, a forward-flexed posture, and the use of small steps when walking; speech and swallowing disturbances; and other symptoms such as a mask-like facial expression or small handwriting are examples of the range of common motor problems that can appear.[1]

Cardinal signs

Four motor signs are considered cardinal in PD: tremor, rigidity, bradykinesia, and postural instability (also referred to as parkinsonism).[1]

... immobile patients who become excited may be able to make quick movements such as catching a ball (or may be able to suddenly run if someone screams "fire"). This phenomenon (kinesia paradoxica) suggests that patients with PD have intact motor programmes, but have difficulties accessing them without an external trigger, such as a loud noise, marching music, or a visual cue requiring them to step over an obstacle.[1]

Other motor symptoms

Drawing of a Parkinson's disease patient face showing hypomimia. Depiction appeared in Nouvelle Iconographie de la Salpètrière, vol 1 (1888).
Example of writing by a patient with Parkinson's disease, possibly showing micrographia in addition to other abnormal characteristics. published by Jean-Martin Charcot in 1879: Text accompanying image stated, "The strokes forming the letters are very irregular and sinuous, whilst the irregularities and sinuosities are of a very limited width. On a careful examination of this specimen of writing, it will be perceived that the down-strokes are all, with the exception of the first letter, made with comparative firmness and are, in fact, nearly normal—the finer up-strokes, on the contrary, are all tremulous in appearance, and it is to the unsteadiness of these lines that the peculiar character of the writing here is principally due."

Other motor symptoms include:

Neuropsychiatric

Parkinson's disease causes neuropsychiatric disturbances, which mainly include cognitive disorders, mood disorders, and behavior problems, and can be as disabling as motor symptoms.[1]

Since L-Dopa, the widely used drug in Parkinson's disease treatment, is decarboxylated by aromatic L-amino acid decarboxylase (AADC), which is found in both dopaminergic and serotonergic neurons, it is possible for serotonergic neurons to convert L-Dopa into dopamine and generate excessive neuronal death by creating reactive oxygen species and quinoproteins. The association of serotonin with mood and cognition may explain some of the side-effects observed in patients treated with L-Dopa due to serotonin deficit.[9][10]

In most cases, motor symptoms predominate at early PD stages, while cognitive disturbances (such as mild cognitive impairment or dementia) emerge later.[11] The onset of parkinsonism in PD relative to dementia is used as an arbitrary criterion to clinically distinguish Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) using a 'one-year rule'.[11] Dementia onset within 12-months of or at the same time as motor dysfunctions qualified as DLB, whereas in PDD, parkinsonism had to precede dementia by at least one year.[11]

Cognitive disturbances occur even in the initial stages of the disease in some cases.[12] A very high proportion of patients have mild cognitive impairment as the disease advances.[1] Most common deficits in nondemented patients are:

Deficits tend to aggravate with time, developing in many cases into dementia. A person with PD has a six-fold increased risk of developing it,[1] and the overall rate in people with the disease is around 30%.[12] Moreover, prevalence of dementia increases in relation to disease duration, going up to 80%.[12] Dementia has been associated with a reduced quality of life in patients and caregivers, increased mortality, and a higher probability of moving to a nursing home.[12]

Cognitive problems and dementia are usually accompanied by behavior and mood alterations, although these kinds of changes are also more common in those patients without cognitive impairment than in the general population. Most frequent mood difficulties include:[1]

Obsessive–compulsive behaviors (also known as impulse-control disorders) such as craving, binge eating, hypersexuality, pathological gambling, punding, or others, can also appear in PD, and have been related to a dopamine dysregulation syndrome associated with the medications for the disease.[1]

Psychotic symptoms are common in PD, generally associated with dopamine therapy. Symptoms of psychosis, or impaired reality testing, are either hallucinations, typically visual, less commonly auditory, and rarely in other domains including tactile, gustatory, or olfactory, or delusions, that is, irrational beliefs. Hallucinations are generally stereotyped and without emotional content. Initially, patients usually have insight so that the hallucinations are benign in terms of their immediate impact, but have poor prognostic implications, with increased risk of dementia, worsened psychotic symptoms, and mortality. Delusions occur in about 5-10% of treated patients, and are considerably more disruptive, being paranoid in nature, of spousal infidelity or family abandonment. Psychosis is an independent risk factor for nursing-home placement.[23]

Hallucinations can occur in parkinsonian syndromes for a variety of reasons. An overlap exists between PD and dementia with Lewy bodies, so that where Lewy bodies are present in the visual cortex, hallucinations may result. Hallucinations can also be brought about by excessive dopaminergic stimulation. Most hallucinations are visual in nature, often formed as familiar people or animals, and are generally not threatening in nature. Some patients find them comforting; however, their caregivers often find this part of the disease most disturbing, and the occurrence of hallucinations is a major risk factor for hospitalisation. Treatment options consist of modifying the dosage of dopaminergic drugs taken each day, adding an antipsychotic drug such as quetiapine, or offering caregivers a psychosocial intervention to help them cope with the hallucinations.

Sleep

Rapid eye movement sleep is altered in PD as opposed to the shown EEG polysomnographic record representing normal REM.

Sleep problems can be worsened by medications for PD, but they are a core feature of the disease.[1] Sleep dysfunction in PD has significant negative impacts on both patient and carer quality of life.[24] Some common symptoms are:

Perception

Autonomic

Gastrointestinal

Parkinson's Disease causes constipation and gastric dysmotility that is severe enough to endanger comfort and even health.[26] A factor in this is the appearance of Lewy bodies and Lewy neurites even before these affect the functioning of the substantia nigra in the neurons in the enteric nervous system that control gut functions.[27]

Neuro-ophthalmological

PD is related to different ophthalmological abnormalities produced by the neurological changes.[1][28] Among them are:

References

  1. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl bm bn bo bp bq br bs bt bu bv bw Jankovic J (April 2008). "Parkinson's disease: clinical features and diagnosis". J. Neurol. Neurosurg. Psychiatry. 79 (4): 368–76. doi:10.1136/jnnp.2007.131045. PMID 18344392.
  2. ^ a b Cooper G, Eichhorn G, Rodnitzky RL (2008). "Parkinson's disease". In Conn PM (ed.). Neuroscience in medicine. Totowa: Humana Press. pp. 508–512. ISBN 978-1-60327-454-8.
  3. ^ a b c d Samii A, Nutt JG, Ransom BR (May 2004). "Parkinson's disease". Lancet. 363 (9423): 1783–93. doi:10.1016/S0140-6736(04)16305-8. PMID 15172778. S2CID 35364322.
  4. ^ Banich MT, Compton RJ (2011). "Motor control". Cognitive neuroscience. Belmont, CA: Wadsworth, Cengage learning. pp. 108–44. ISBN 978-0-8400-3298-0.
  5. ^ Fung VS, Thompson PD (2007). "Rigidity and spasticity". In Tolosa E, Jankovic JJ (eds.). Parkinson's disease and movement disorders. Hagerstown, MD: Lippincott Williams & Wilkins. pp. 504–13. ISBN 978-0-7817-7881-7.
  6. ^ Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. (December 2009). "Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms". Lancet Neurol. 8 (12): 1128–39. doi:10.1016/S1474-4422(09)70293-5. PMID 19909911. S2CID 16415964.
  7. ^ Lepoutre A, Devos D, Blanchard-Dauphin A, et al. (2006). "A specific clinical pattern of camptocormia in Parkinson's disease". J. Neurol. Neurosurg. Psychiatry. 77 (11): 1229–34. doi:10.1136/jnnp.2005.083998. PMC 2077366. PMID 16735399.
  8. ^ Aarsland D, Brønnick K, Ehrt U, et al. (January 2007). "Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress". Journal of Neurology, Neurosurgery, and Psychiatry. 78 (1): 36–42. doi:10.1136/jnnp.2005.083113. PMC 2117797. PMID 16820421.
  9. ^ Stansley, B. J., & Yamamoto, B. K. (2012). L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells. Neuropharmacology, 67, 243–251. doi:10.1016/j.neuropharm.2012.11.010
  10. ^ Stansley, B. J., & Yamamoto, B. K. (2015). L-Dopa and Brain Serotonin System Dysfunction. Toxics, 3(1), 75–88. doi:10.3390/toxics3010075
  11. ^ a b c Saeed, U; Compagnone, J; Aviv, RI; Strafella, AP; Black, SE; Lang, AE; Masellis, M (2017). "Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts". Translational Neurodegeneration. 6 (8): 8. doi:10.1186/s40035-017-0076-6. PMC 5370489. PMID 28360997.
  12. ^ a b c d e f g h i Caballol N, Martí MJ, Tolosa E (September 2007). "Cognitive dysfunction and dementia in Parkinson disease". Mov. Disord. 22 (Suppl 17): S358–66. doi:10.1002/mds.21677. PMID 18175397. S2CID 3229727.
  13. ^ Reinders, JS (Jan 2008). "A systematic review of prevalence studies of depression in Parkinson's disease". Movement Disorders. 23 (2): 183–9, quiz 313. doi:10.1002/mds.21803. hdl:1956/4068. PMID 17987654. S2CID 16613346.
  14. ^ Lieberman A (January 2006). "Depression in Parkinson's disease -- a review". Acta Neurologica Scandinavica. 113 (1): 1–8. doi:10.1111/j.1600-0404.2006.00536.x. PMID 16367891. S2CID 35349675.
  15. ^ Ishihara L, Brayne C (April 2006). "A systematic review of depression and mental illness preceding Parkinson's disease". Acta Neurologica Scandinavica. 113 (4): 211–20. doi:10.1111/j.1600-0404.2006.00579.x. PMID 16542159. S2CID 249341.
  16. ^ Gustafsson, H (June 2015). "Depression and subsequent risk of Parkinson disease: A nationwide cohort study". Neurology. 84 (24): 2422–9. doi:10.1212/WNL.0000000000001684. PMC 4478031. PMID 25995056.
  17. ^ McDonald W; Richard, IH; Delong, MR (2003). "Prevalence, Etiology, and Treatment of Depression in Parkinson's Disease". Biol Psychiatry. 54 (3): 363–375. doi:10.1016/S0006-3223(03)00530-4. PMID 12893111. S2CID 45520438.
  18. ^ Leentjens, Albert F. (2015). "Parkinson disease: Depression—risk factor or early symptom in Parkinson disease?". Nature Reviews Neurology. 11 (8): 432–433. doi:10.1038/nrneurol.2015.126. PMID 26215622. S2CID 11364065.
  19. ^ Leentjens, Albert F. G.; Moonen, Anja J. H.; Dujardin, Kathy; Marsh, Laura; Martinez-Martin, Pablo; Richard, Irene H.; Starkstein, Sergio E.; Köhler, Sebastian (2013-09-17). "Modeling depression in Parkinson disease Disease-specific and nonspecific risk factors". Neurology. 81 (12): 1036–1043. doi:10.1212/WNL.0b013e3182a4a503. ISSN 0028-3878. PMC 3795592. PMID 23946309.
  20. ^ Menza, Matthew Combating Depression in Parkinson's Disease. Parkinson's Disease Foundation News & Review. Spring 2009.
  21. ^ Menza MA. Psychiatric symptoms associated with Parkinson disease. Drug Benefit Trends. 2010;22:58-60.
  22. ^ The National Collaborating Centre for Chronic Conditions, ed. (2006). "Non-motor features of Parkinson's disease". Parkinson's Disease. London: Royal College of Physicians. pp. 113–33. ISBN 978-1-86016-283-1.
  23. ^ Friedman JH (June 2010). "Parkinson's disease psychosis 2010: A review article". Parkinsonism Relat Disord. 16 (9): 553–60. doi:10.1016/j.parkreldis.2010.05.004. PMID 20538500.
  24. ^ Hunt, Jeremy; Coulson, Elizabeth J.; Rajnarayanan, Rajendram; Oster, Henrik; Videnovic, Aleksandar; Rawashdeh, Oliver (2022-01-09). "Sleep and circadian rhythms in Parkinson's disease and preclinical models". Molecular Neurodegeneration. 17 (1): 2. doi:10.1186/s13024-021-00504-w. ISSN 1750-1326. PMC 8744293. PMID 35000606.
  25. ^ Gupta AK, Bluhm R (January 2004). "Seborrheic dermatitis". Journal of the European Academy of Dermatology and Venereology. 18 (1): 13–26, quiz 19–20. doi:10.1111/j.1468-3083.2004.00693.x. PMID 14678527. S2CID 45180745.
  26. ^ Pfeiffer RF (February 2003). "Gastrointestinal dysfunction in Parkinson's disease". Lancet Neurology. 2 (2): 107–16. doi:10.1016/S1474-4422(03)00307-7. PMID 12849267. S2CID 21009040.
  27. ^ Lebouvier T, Chaumette T, Paillusson S, et al. (September 2009). "The second brain and Parkinson's disease". The European Journal of Neuroscience. 30 (5): 735–41. doi:10.1111/j.1460-9568.2009.06873.x. PMID 19712093. S2CID 1024997.
  28. ^ a b c Armstrong RA (March 2008). "Visual signs and symptoms of Parkinson's disease". Clin Exp Optom. 91 (2): 129–38. doi:10.1111/j.1444-0938.2007.00211.x. PMID 18271776. S2CID 26202780.
  29. ^ Gitchel GT, Wetzel PA, Baron MS (2012). "Pervasive ocular tremor in patients with Parkinson disease". Arch Neurol. 69 (8): 1011–7. doi:10.1001/archneurol.2012.70. PMID 22490323.
  30. ^ Uc EY; Rizzo, M; Anderson, SW; Sparks, J; Rodnitzky, RL; Dawson, JD (2006). "Impaired visual search in drivers with Parkinson's disease". Annals of Neurology. 60 (4): 407–13. doi:10.1002/ana.20958. PMID 16969860. S2CID 40915704.